Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290569 | 0.87 | MAPT (0.41) | PIK3CDMAPTP2RX7GAATDP1 | |
| SCHEMBL13290579 | 0.87 | MAPT (0.41) | PIK3CDMAPTP2RX7GAATDP1 | |
| SCHEMBL9834032 | 0.87 | MAPT (0.41) | PIK3CDMAPTP2RX7GAATDP1 | |
| SCHEMBL13513137 | 0.84 | — | — | |
| SCHEMBL13298015 | 0.79 | BRD4 (0.43) | PIK3CDBRD4CRBNBRD2 | |
| SCHEMBL19546202 | 0.79 | BRD4 (0.43) | PIK3CDBRD4CRBNBRD2 | |
| SCHEMBL124340 | 0.79 | BRD4 (0.43) | PIK3CDBRD4CRBNBRD2 | |
| SCHEMBL19546734 | 0.79 | BRD4 (0.43) | PIK3CDBRD4CRBNBRD2 | |
| SCHEMBL14544573 | 0.79 | BRD4 (0.43) | PIK3CDBRD4CRBNBRD2 | |
| SCHEMBL12748060 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9840479-B2 | Polyamine-fatty acid derived lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-12 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | PIK3CD 739/4885MAPT 4133/4885BRD4 3443/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | PIK3CD 828/4885MAPT 4391/4885BRD4 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.